| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | New England Journal of Medicine | 2009 | 6.3K |
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Science | 2007 | 3.7K |
| Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 2.8K |
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | American Journal of Human Genetics | 2003 | 2.6K |
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | New England Journal of Medicine | 2014 | 2.1K |
| Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer | New England Journal of Medicine | 2017 | 1.8K |
| The increasing dominance of teams in production of knowledge | Science | 2007 | 1.7K |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 1.7K |
| Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis | American Journal of Human Genetics | 1998 | 1.3K |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial | Lancet, The | 2019 | 1.3K |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1.1K |
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial | Lancet, The | 2008 | 1.1K |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 897 |
| Nasopharyngeal carcinoma | Lancet, The | 2016 | 799 |
| Nasopharyngeal carcinoma | Lancet, The | 2019 | 747 |
| Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | Journal of Clinical Oncology | 2020 | 600 |
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab | Nature Medicine | 2018 | 581 |
| Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients | Journal of Clinical Oncology | 2007 | 567 |
| Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 559 |
| Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | Lancet Oncology, The | 2015 | 551 |
| Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors | Journal of Medical Virology | 2000 | 520 |
| Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab | Journal of Clinical Oncology | 2009 | 507 |
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma | Journal of the National Cancer Institute | 2005 | 490 |
| Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience | International Journal of Radiation Oncology Biology Physics | 2005 | 468 |
| Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients | Cancer | 2002 | 455 |
